Cincinnati, Ohio 45267


Purpose:

The purpose of this research study is to test the safety of adding metformin to standard of care. The standard of care treatment will be cisplatin once every 3 weeks for 3 treatments and radiation for 7 weeks. Metformin is a medication that is currently used to treat diabetes. Increasing amounts of metformin will be given to groups of patients already receiving normal treatment for their cancer to see if metformin causes any good effects by killing your cancer or bad effects (side effects).


Criteria:

Inclusion Criteria: - Locally advanced squamous cell cancer of the head and neck, stage III or IV disease (T1-2, N2a-3 or T3-4). - Measurable disease - No prior chemotherapy or radiation for head and neck squamous cell cancer - Life expectancy of greater than 3 months. - Adequate labs Exclusion Criteria: - Known metastatic disease. - Nasopharyngeal carcinoma - History of allergic reactions attributed to metformin or other agents used in study. - Known diagnosis of diabetes requiring insulin for control. - Administration of metformin within last 4 weeks.


NCT ID:

NCT02325401


Primary Contact:

Principal Investigator
Trisha Wise-Draper, MD
University of Cincinnati

UC Cancer Institute Clinical Trials Office
Phone: 513-584-7698
Email: kastla@ucmail.uc.edu


Backup Contact:

N/A


Location Contact:

Cincinnati, Ohio 45267
United States

UC Cancer Institute Clinical Trials Office
Phone: 513-584-7698
Email: kastla@ucmail.uc.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.